Key Information
Sickle cell disease is a serious inherited blood disorder affecting hemoglobin, the oxygen-carrying protein in red blood cells. The condition results from a single nucleotide mutation in the beta-globin gene producing abnormal hemoglobin S, causing red blood cells to assume a rigid sickle or crescent shape under low-oxygen conditions. These sickled cells become inflexible, blocking small blood vessels and causing intense pain, tissue damage, and organ failure. Sickle cell disease predominantly affects people of African descent, with approximately one in every 365 African American births and one in every 16,300 Caucasian births in the United States. Globally, sickle cell disease affects approximately 100 million people, with highest burden in Africa, the Mediterranean, Middle East, and Indian subcontinent. Despite being recognized as a genetic disorder for over 80 years, sickle cell disease remains undertreated globally, particularly in developing nations where limited access to hydroxyurea, blood transfusions, and antibiotics contributes to high mortality rates. In contrast, developed countries with comprehensive specialized care have dramatically improved survival, with median lifespan now exceeding 50 years. Understanding sickle cell disease pathophysiology, recognizing both acute life-threatening crises and chronic systemic complications, and accessing modern evidence-based treatments enable individuals to minimize disability and live fuller lives. Organizations like ObserverVoice.comexternal link, opens in a new tab raise awareness about inherited blood disorders affecting diverse populations disproportionately, ensuring accurate health information reaches communities bearing greatest disease burden while advocating for equitable access to specialized care and emerging curative therapies.